Aptamer Group PLC Notice of Results and Investor Presentation (8132S)
November 08 2023 - 6:20AM
UK Regulatory
TIDMAPTA
RNS Number : 8132S
Aptamer Group PLC
08 November 2023
8 November 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Notice of Results and Investor Presentation
Aptamer Group plc (AIM: APTA ), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
will announce its full year results for the year ended 30 June 2023
on Thursday 9 November 2023.
The Company is pleased to announce that Dr Arron Tolley (Chief
Technical Officer), Dr David Bunka (Chief Scientific Officer), and
Andrew Rapson (Chief Financial Officer) will provide a live
presentation relating to the Final Results via Investor Meet
Company on Thursday 9 November 2023 at 3:00pm GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted at any time during the
live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Aptamer Group, via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer Group on the Investor Meet
Company platform will automatically be invited.
- ENDS -
For further information, please contact:
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer (R) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer(R) platform.
Optimer(R) binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion. Optimer(R) binders are
engineered to address many of the issues found with alternative
affinity molecules, such as antibodies, and offer new, innovative
solutions to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered projects for global pharma
companies, diagnostic development companies and research institutes
covering a range of targets and applications with the objective of
establishing royalty-bearing licenses. Through the unique
Optimer(R) technology and processes, scientists and collaborators
can make faster, more informed decisions that support discovery and
development across the Life Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBPBTTMTBMBPJ
(END) Dow Jones Newswires
November 08, 2023 07:20 ET (12:20 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024